Lesson plan
Actoxumab
Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infection. This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School. The project was then licensed to Merck & Co., Inc. for further development and commercialization. A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.
Article summary
Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infection. This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School. The project was then licensed to Merck & Co., Inc. for further development and commercialization. A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.